Verastem Oncology Completes Rolling Nda Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer
Verastem腫瘤學公司完成了對Avutometinib加Defactinib作爲治療複發性Kras突變低級別漿液性卵巢癌的滾動NDA提交給FDA。
Verastem Oncology Completes Rolling Nda Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer
Verastem腫瘤學公司完成了對Avutometinib加Defactinib作爲治療複發性Kras突變低級別漿液性卵巢癌的滾動NDA提交給FDA。
譯文內容由第三人軟體翻譯。